Spots Global Cancer Trial Database for Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients
Official Title: A Prospective Multicenter Randomized Controlled Open-label Trial of Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients
Study ID: NCT02956772
Conditions
Study Description
Brief Summary: A multicentre, randomized, open-label, parallel-group, active controlled study.
Detailed Description: Primary hepatocellular carcinoma (HCC) is one of the most common types of cancer and accounts for significant morbidity and mortality worldwide. Notably, more than half of the new HCC cases and deaths develop in China. Transarterial chemoembolization (TACE) has been proposed as the first-line therapeutic strategy for the treatment of patients with unresectable HCC. However, TACE has several limitations itself which might be potentially associated with tumor metastasis and relapse. Recent studies have demonstrated that arsenic trioxide (As2O3) can act as the first-line therapeutic option in the treatment of acute promyelocytic leukemia. Thereafter, several small studies in China showed promising clinical benefits when As2O3 is administrated among the HCC patients. With these preliminary results, the investigators are planning to carry out a multicenter randomized controlled trial through which to explore the potential efficacy and safety of adjuvant As2O3 treatment for HCC patients.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Guizhou Cancer Hospital, Guiyang, Guizhou, China
Guizhou Province Tumor Hospital, Guiyang, Guizhou, China
Hunan Provincial People's Hospital, Changsha, Hunan, China
Hunan Cancer Hospital, Changsha, Hunan, China
Xiangya Hospital Central South University, Changsha, Hunan, China
The First Affiliated Hospital of University of South China, Hengyang, Hunan, China
Jiangsu Province Hospital, Nanjing, Jiangsu, China
Xinjiang Medical University Cancer Hospital, Urumqi, Xinjiang, China
The Tumor Hospital of Yunnan Province, Kunming, Yunnan, China
Contact Details
Name: Hua Xiang, Dr.
Affiliation: Hunan Provincial People's Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
